Hansoh (3692) Announces NDA Acceptance for HS-10365 Capsules by NMPA

Bulletin Express

Oct 23

Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365 capsules. HS-10365 is described as a potent and selective rearranged during transfection (RET) inhibitor, intended for adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer.

According to the announcement, this development represents a significant milestone in the Group’s efforts to advance treatments for RET fusion-positive NSCLC. The application’s acceptance marks an important regulatory step and reflects progress in the company’s innovative drug pipeline. The chairlady of the board, Zhong Huijuan, issued the announcement on behalf of Hansoh Pharmaceutical Group Company Limited on October 23, 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1161900024"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161900024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161900024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161900024","market":"hk","top_or_hot":-1,"title":"Hansoh (3692) Announces NDA Acceptance for HS-10365 Capsules by NMPA","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365 capsules. HS-10365 is described as a potent and selective rearranged during transfection (RET) inhibitor, intended for adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer.</p>\n<p>According to the announcement, this development represents a significant milestone in the Group’s efforts to advance treatments for RET fusion-positive NSCLC. The application’s acceptance marks an important regulatory step and reflects progress in the company’s innovative drug pipeline. The chairlady of the board, Zhong Huijuan, issued the announcement on behalf of Hansoh Pharmaceutical Group Company Limited on October 23, 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh (3692) Announces NDA Acceptance for HS-10365 Capsules by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh (3692) Announces NDA Acceptance for HS-10365 Capsules by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-23 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365 capsules. HS-10365 is described as a potent and selective rearranged during transfection (RET) inhibitor, intended for adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer.</p>\n<p>According to the announcement, this development represents a significant milestone in the Group’s efforts to advance treatments for RET fusion-positive NSCLC. The application’s acceptance marks an important regulatory step and reflects progress in the company’s innovative drug pipeline. The chairlady of the board, Zhong Huijuan, issued the announcement on behalf of Hansoh Pharmaceutical Group Company Limited on October 23, 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1161900024","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161900024","pubTimestamp":1761220805,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"豪森（3692）公布HS-10365胶囊获NMPA NDA受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365 capsules. HS-10365 is described as a potent and selective rearranged during transfection (RET) inhibitor, intended for adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer.\nAccording to the announcement, this development represents a significant milestone in the Group’s efforts to advance treatments for RET fusion-positive NSCLC. The application’s acceptance marks an important regulatory step and reflects progress in the company’s innovative drug pipeline. The chairlady of the board, Zhong Huijuan, issued the announcement on behalf of Hansoh Pharmaceutical Group Company Limited on October 23, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}